Article
Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations.
Cytokine & growth factor reviews - 1 Apr 2023
He Qiangqiang, Qu Meiyu, Bao Hangyang, Xu Yana, Shen Tingyu, Tan Dan, Barkat Muhammad Qasim, Xu Chengyun, Zeng Ling-Hui, Wu Ximei
Abstract excerpt
Epidermal growth factor receptor (EGFR) mutation is the most common driver mutation in non-small cell lung cancer (NSCLC). The first-line therapy for advanced NSCLC patients with EGFR-sensitive mutation is the EGFR tyrosine kinase inhibitor (EGFR-TKI). However, most NSCLC patients with EGFR mutation will develop resistant mutations in EGFR-TKI therapy. With further studies, resistance mechanisms represented by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.